share_log

Protalix BioTherapeutics Analyst Ratings

Protalix BioTherapeutics Analyst Ratings

Protalix 生物療法分析師評級
Benzinga ·  2023/11/14 19:49
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/14/2023 669.23% HC Wainwright & Co. → $10 Reiterates Buy → Buy
10/31/2023 669.23% HC Wainwright & Co. $7 → $10 Maintains Buy
05/03/2021 438.46% HC Wainwright & Co. $11 → $7 Maintains Buy
06/08/2020 746.15% HC Wainwright & Co. $3 → $11 Maintains Buy
日期 上行/下行 分析公司 目標價格變動 評級變動 之前/當前的評級
11/14/2023 669.23% HC Wainwright & Co. → 10 美元 重申 購買 → 購買
10/31/2023 669.23% HC Wainwright & Co. 7 美元 → 10 美元 維護
05/03/2021 438.46% HC Wainwright & Co. 11 美元 → 7 美元 維護
06/08/2020 746.15% HC Wainwright & Co. 3 美元 → 11 美元 維護

What is the target price for Protalix BioTherapeutics (PLX)?

Protalix BioTherapeutics(PLX)的目標價格是多少?

The latest price target for Protalix BioTherapeutics (AMEX: PLX) was reported by HC Wainwright & Co. on November 14, 2023. The analyst firm set a price target for $10.00 expecting PLX to rise to within 12 months (a possible 669.23% upside). 2 analyst firms have reported ratings in the last year.

HC Wainwright & Co. 於2023年11月14日公佈了Protalix BioTherapeutics(美國證券交易所股票代碼:PLX)的最新目標價格。該分析公司將目標股價定爲10.00美元,預計PLX將在12個月內升至12個月內(可能上漲669.23%)。去年有兩家分析公司公佈了評級。

What is the most recent analyst rating for Protalix BioTherapeutics (PLX)?

Protalix BioTherapeutics(PLX)的最新分析師評級是多少?

The latest analyst rating for Protalix BioTherapeutics (AMEX: PLX) was provided by HC Wainwright & Co., and Protalix BioTherapeutics reiterated their buy rating.

HC Wainwright & Co. 提供了Protalix BioTherapeutics(美國證券交易所股票代碼:PLX)的最新分析師評級,Protalix BioTherapeutics重申了其買入評級。

When is the next analyst rating going to be posted or updated for Protalix BioTherapeutics (PLX)?

Protalix BioTherapeutics(PLX)的下一次分析師評級何時公佈或更新?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Protalix BioTherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Protalix BioTherapeutics was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.

分析師在進行了廣泛的研究後得出了股票評級,其中包括瀏覽公開財務報表,與Protalix BioTherapeutics的高管和客戶交談,以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級,因此每家公司每年應該獲得4次評級。Protalix BioTherapeutics的最新評級是在2023年11月14日公佈的,因此您應該預計下一個評級將在2024年11月14日左右公佈。

Is the Analyst Rating Protalix BioTherapeutics (PLX) correct?

分析師對Protalix BioTherapeutics(PLX)的評級是否正確?

While ratings are subjective and will change, the latest Protalix BioTherapeutics (PLX) rating was a reiterated with a price target of $0.00 to $10.00. The current price Protalix BioTherapeutics (PLX) is trading at is $1.30, which is within the analyst's predicted range.

儘管評級是主觀的,並且會發生變化,但最新的Protalix BioTherapeutics(PLX)評級得到了重申,目標股價爲0.00美元至10.00美元。Protalix BioTherapeutics(PLX)目前的交易價格爲1.30美元,在分析師的預測區間內。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論